Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/ResMed leads sleep apnea market with strong growth and margin improvements, rated Buy with 12% safety margin.
RMD
$198.93
-$1.36 -0.68%

ResMed leads sleep apnea market with strong growth and margin improvements, rated Buy with 12% safety margin.

Analyst Insights
29 Jun 2026
Seeking Alpha
View Source
Bullish
pluang ai news

ResMed (RMD) dominates the sleep apnea market with a 62% share in a large, under-penetrated market offering significant growth potential. The company benefits from a razor-and-blade business model, strong brand loyalty, and recurring revenue from low-cost consumables. Financially, ResMed shows consistent sales and earnings growth without misses for over a decade, supported by recent CMS exclusions and tariff exemptions that improve margins. The analyst values the stock with a 12% margin of safety and recommends buying, highlighting its resilience and predictable business model.

More News (RMD)

Nyxoah sees Orin Hirchman cross 10% voting rights threshold, Resmed drops below 3%.

Nyxoah sees Orin Hirchman cross 10% voting rights threshold, Resmed drops below 3%.

Nyxoah SA announced that Orin Hirchman, through controlled entities, acquired 14.55% of voting rights as of June 10, 2026, surpassing the 10% disclosure threshold. Meanwhile, Resmed Inc. reduced its stake to 1.95%, falling below the 3% threshold. The...

Market News
Neutral
8 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App